Published on
May 9, 2026
FDA Extends Review of Eisai, Biogen Alzheimer's Drug
KEY POINTS FDA extends review of weekly subcutaneous LEQEMBI IQLIK for early Alzheimer's initial treatment to Aug. 24, 2026 Review delay follows a major amendment after an FDA request for additional information FDA has not raised concerns about …
Source:
International Business Times
-
Center-left
